Show simple item record

dc.contributor.advisorReyes, Juan Manuel 
dc.contributor.advisorFierro Urresta, Marco Aurelio 
dc.creatorRada Pineda, Alvaro Javier 
dc.date.accessioned2016-02-10T19:49:40Z
dc.date.available2016-02-10T19:49:40Z
dc.date.created2016-01-08
dc.date.issued2016 
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/11711
dc.descriptionResumen Introducción Una posible opción de tratamiento para el manejo del trastorno depresivo mayor (TDM) es la estimulación magnética transcraneal (EMT) que ha mostrado propiedades antidepresivas superiores al placebo con un buen perfil de seguridad. El objetivo del presente trabajo es determinar la reducción en la severidad del TDM y la proporción de eventos adversos (EA) en pacientes con TDM refractario y no refractario, posterior al uso de EMT administrada en monoterapia o tratamiento coadyuvante comparado con terapia farmacológica. Metodología Se planteó una pregunta PICOT de la cual se realizó una búsqueda sistemática de estudios clínicos en las bases de datos Medline, EMBASE y Cochrane. Dos investigadores en forma independiente realizaron la selección de artículos, evaluación de calidad con la herramienta de la colaboración Cochrane y extracción de datos. Se extrajeron datos de eficacia como tasa de respuesta, porcentaje de remisión, calidad de vida, diminución sintomática del trastorno depresivo mayor en la escala de Hamilton y capacidad funcional. Igualmente, proporción de pacientes con EA. Se realizó un meta-análisis de estas variables teniendo en cuenta la heterogeneidad. Resultados La presente revisión sistemática incluyó 26 estudios clínicos aleatorizados de baja calidad metodológica mostrando que la EMT presentó una eficacia superior cuando es usada como coadyuvante a las terapias con que venían siendo tratados los pacientes con TDM refractario y no refractario en los desenlaces de tasa de respuesta y porcentaje de remisión. En el caso de intervenciones farmacológicas específicas, la EMT presento eficacia similar, tanto en terapia coadyuvante como en monoterapia comparado con las intervenciones farmacológicas. En cuanto a seguridad, la EMT presenta un buen perfil de seguridad debido a que en todos los escenarios estudiados los EA fueron no serios y baja frecuencia Conclusiones La evidencia disponible sugiere que la EMT mostró ser efectivo y seguro para el manejo del TDM refractario y no refractario. Sin embargo, la evidencia es débil por lo tanto se necesita mayor investigación clínica que soporte su uso.
dc.description.abstractAbstract Introduction One possible treatment option for the management of major depressive disorder (MDD) is transcranial magnetic stimulation (TMS) which has shown antidepressant properties superior to placebo with a good safety profile. The aim of this study is to determine the reduction in the severity of MDD and proportion of adverse events (AEs) in patients with refractory and non-refractory MDD, following the use of TMS administered as monotherapy or adjunctive therapy compared to pharmacological therapy. Methodology A systematic search of a PICOT question was performed in the Medline, EMBASE and Cochrane database. Two investigators independently selected citations, assessed of quality using Cochrane Collaboration tool and collected the data. Efficacy data were extracted such as response rate, remission rate, quality of life, symptoms decrease of major depressive disorder in the Hamilton scale and functional capacity. Similarly, proportion of patients with AEs. A meta-analysis of these variables was performed taking into account the heterogeneity. Results This systematic review included 26 randomized trials with low methodological quality showing that TMS had superior efficacy when was used as an adjunct to therapies that were being treated patients with refractory MDD and non-refractory in the outcomes of response rate and percentage of remission. In the case of specific pharmacological interventions, TMS has similarly effective in both monotherapy and adjunctive therapy compared to pharmacological interventions. Regarding to safety, the TMS had a good safety profile because in all scenarios studied the AE were not serious and low frequency Conclusions The available evidence suggests that TMS show to be effective and safe for the management of refractory and non-refractory MDD. However, the evidence is weak therefore major clinical research is necessary in order to support its use.
dc.description.sponsorshipUniversidad del Rosario
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.subjectEstimulacion Magnetica Transcraneal
dc.subjectTrastorno depresivo mayor
dc.subject.ddcPsicología 
dc.subject.lembPsicología
dc.titleEficacia de la estimulación magnética transcraneal en la disminución de severidad en el trastorno depresivo mayor en monoterapia y coadyuvante comparado con tratamientos farmacológicos. Revisión sistemática y meta-análisis
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Psiquiatría
dc.publisher.programEspecialización en Psiquiatría
dc.publisher.departmentFacultad de Medicina
dc.subject.keywordTranscranial Magnetic Stimulation
dc.subject.keywordmajor depressive disorder
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsEstimulación magnética transcraneal
dc.subject.decsDepresión
dc.subject.decsMedicina de la conducta
dc.subject.decsUtilización de medicamentos
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationLópez-Ibor J, Pastrana J, Cisneros S, López-Ibor M. Eficacia de la estimulación magnética transcraneal en depresión. Estudio naturalístico. Actas Esp Psiquiatr. 2010;38(2).
dc.source.bibliographicCitationWorld Health Organization. The global burden of disease 2004 update. Geneva: WHO Press, World Health Organization; 2008.
dc.source.bibliographicCitationSansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012 May;9(5-6):41–6.
dc.source.bibliographicCitationWarden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007 Dec;9(6):449–59.
dc.source.bibliographicCitationBurt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002 Mar;5(1):73–103.
dc.source.bibliographicCitationKozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract. 2002 Sep;8(5):270–5.
dc.source.bibliographicCitationCouturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. J Psychiatry Neurosci. 2005 Mar;30(2):83–90.
dc.source.bibliographicCitationBerlim MT, Van den Eynde F, Daskalakis ZJ. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of randomized, double-blind, and sham-controlled trials. J Clin Psychiatry.2013 Feb;74(2):e122–9.
dc.source.bibliographicCitationLiu B, Zhang Y, Zhang L, Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. BMC Psychiatry. 2014 Jan;14:342.
dc.source.bibliographicCitationPascual-Leone A, Tormos-Muñoz J. Estimulación magnética transcraneal: fundamentos y potencial de la modulación de redes neurales específicas. REV NEUROL. 2008;46(Supl 1):S3–10.
dc.source.bibliographicCitationNational Institute for Health and Clinical Excellence. Depression: Evidence Update April 2012. A summary of selected new evidence relevant to NICE clinical guideline 90 ‘The treatment and management of depression in adults. 2009.
dc.source.bibliographicCitationWorld Health Organization. Depresión [Internet]. Temas de Salud. 2015. Available from: http://www.who.int/topics/depression/es/World Health Organization. Depression. Fact Sheet 369. 2012;1–4.
dc.source.bibliographicCitationOlarte R, Pedraza J, Ojeda G. Análisis de la depresión en el adulto mayor en la encuesta nacional de demografía y salud 2010. Bogotá; 2012.
dc.source.bibliographicCitationSimon GE, Goldberg DP, Von Korff M, Ustün TB. Understanding cross-national differences in depression prevalence. Psychol Med. 2002 May;32(4):585–94.
dc.source.bibliographicCitationKessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003 Jun 18;289(23):3095–105.
dc.source.bibliographicCitationFrassure-Smith N, Lesperence F. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999–1005.
dc.source.bibliographicCitationEaton W. Epidemiological evidence on the comorbidity of depression and diabetes. J Psychosom Res. 2002;53:903–6.
dc.source.bibliographicCitationMassie M. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;32:56–71.
dc.source.bibliographicCitationRugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002 Jul;23(1):51–61.
dc.source.bibliographicCitationLuppa M, Heinrich S, Angermeyer MC, König H-H, Riedel-Heller SG. Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007 Feb;98(1-2):29–43.
dc.source.bibliographicCitationGomez C, Bohorquez A. Detección temprana y diagnóstico del episodio depresivo y trastorno depresivo recurrente en adultos. Atención integral de los adultos con diagnóstico de episodio depresivo o trastorno depresivo recurrente. Bogota, Colombia: Ministerio de Salud y Protección Social - Colciencias; 2013.
dc.source.bibliographicCitationEitan R, Lerer B. Nonpharmacological, somatic treatments of depression: Dialogues, electroconvulsive therapy and novel brain stimulation modalities. Clin Neurosci. 2006;8(2):241–58.
dc.source.bibliographicCitationEitan R, Lerer B. Nonpharmacological, somatic treatments of depression: Dialogues, electroconvulsive therapy and novel brain stimulation modalities. Clin Neurosci. 2006;8(2):241–58.
dc.source.bibliographicCitationBerlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014 Jan;44(2):225–39.
dc.source.bibliographicCitationGaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2014 May;75(5):477–89; quiz 489.
dc.source.bibliographicCitationLepping P, Schönfeldt-Lecuona C, Sambhi RS, Lanka SVN, Lane S, Whittington R, et al. A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. Acta Psychiatr Scand. 2014 Nov;130(5):326–41.
dc.source.bibliographicCitationLam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry. 2008 Sep;53(9):621–31.
dc.source.bibliographicCitationLam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009 Oct;117 Suppl:S26–43.
dc.source.bibliographicCitationHung C-I. Factors predicting adherence to antidepressant treatment. Curr Opin Psychiatry. 2014 Sep;27(5):344–9.
dc.source.bibliographicCitationSadock B, Sadock V. Kaplan & Sadock Sinopsis de Psiquiatria. 10th ed. LIPPINCOTT WILLIAMS AND WILKINS, editor. 2008.
dc.source.bibliographicCitationAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorider. Fifth. Arlington, VA: American Psychiatric Association; 2013.
dc.source.bibliographicCitationO B, A. LM. Actualización Sobre Neurotransmisión Serotoninérgica. Rev Argentina Clínica Neuropsiquiátrica. 1997;4.
dc.source.bibliographicCitationOrtega J, Callado L, Meana J. El sistema noradrenérgico en la neurobiología de la depresión. Psiquiatr Biológica. 2008;15(5).
dc.source.bibliographicCitationBobadilla H, Fierro M. Estimulación magnética transcraneana (EMT). Rev Colomb Psiquiatr. 2002;31(4):313–27.
dc.source.bibliographicCitationHamilton M. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6.
dc.source.bibliographicCitationHamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23.
dc.source.bibliographicCitationRamos-Brieva JC A. A new validation of the Hamilton Rating Scale for Depression. J Psychiatr Res. 1988;22.
dc.source.bibliographicCitationZimmerman M, Chelminski I. Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high? J Nerv Ment Dis. 2005;193(3).
dc.source.bibliographicCitationMuñiz J, Fernandez-Herminda J. La opinión de los psicólogos españoles sobre el uso de los test. Papeles del Psicólogo. 2010;31(1):108–21.
dc.source.bibliographicCitationAmerican Psychological Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 5 th. Association AP, editor. Washington, DC; 2000.
dc.source.bibliographicCitationWorld Health Organization. International Classification of Diseases and Related Health Problems 10th Revision (ICD-10) [Internet]. 10th ed. WHO, editor. Geneva; 2007. Available from: http://apps.who.int/classifications/apps/icd/ icd10online/
dc.source.bibliographicCitationHiggins J, Greens S. Cochrane Handbook for Systematic Review of interventions [Internet]. 5.1.0 ed. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org.
dc.source.bibliographicCitationHuang M, Luo B, Hu J, Wang S-S, Zhou W, Wei N, et al. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial. Aust N Z J Psychiatry [Internet]. 2012 Mar;46(3):257–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22391283
dc.source.bibliographicCitationRumi DO, Gattaz WF, Rigonatti SP, Rosa MA, Fregni F, Rosa MO, et al. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry. 2005 Jan 15;57(2):162–6.
dc.source.bibliographicCitationPadberg F, Zwanzger P, Keck ME, Kathmann N, Mikhaiel P, Ella R, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology. 2002 Oct;27(4):638–45.
dc.source.bibliographicCitationMosimann UP, Schmitt W, Greenberg BD, Kosel M, Müri RM, Berkhoff M, et al. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. Psychiatry Res. 2004 Apr 30;126(2):123–33.
dc.source.bibliographicCitationChistyakov A V, Kaplan B, Rubichek O, Kreinin I, Koren D, Feinsod M, et al. Antidepressant effects of different schedules of repetitive transcranial magnetic stimulation vs. clomipramine in patients with major depression: relationship to changes in cortical excitability. Int J Neuropsychopharmacol. 2005 Jun;8(2):223–33.
dc.source.bibliographicCitationAguirre I, Carretero B, Ibarra O, Kuhalainen J, Martínez J, Ferrer A, et al. Age predicts low-frequency transcranial magnetic stimulation efficacy in major depression. J Affect Disord. 2011 May;130(3):466–9.
dc.source.bibliographicCitationBakim B, Uzun U, Karamustafalioglu K, Ozcelik B, Alpak G, Tankaya O, et al. The Combination of Antidepressant Drug Therapy and High-Frequency Repetitive Transcranial Magnetic Stimulation in Medication-Resistant Depression. Bull Clin Psychopharmacol. 2012;22(3):244–53.
dc.source.bibliographicCitationBares M, Kopecek M, Novak T, Stopkova P, Sos P, Kozeny J, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. J Affect Disord. 2009 Nov;118(1-3):94–100.
dc.source.bibliographicCitationBretlau LG, Lunde M, Lindberg L, Undén M, Dissing S, Bech P. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Pharmacopsychiatry. 2008 Mar;41(2):41–7.
dc.source.bibliographicCitationBrunelin J, Jalenques I, Trojak B, Attal J, Szekely D, Gay A, et al. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT. Brain Stimul. 7(6):855–63.
dc.source.bibliographicCitationChen S-J, Chang C-H, Tsai H-C, Chen S-T, Lin CC. Superior antidepressant effect occurring 1 month after rTMS: add-on rTMS for subjects with medication-resistant depression. Neuropsychiatr Dis Treat. 2013;9:397–401.
dc.source.bibliographicCitationGarcía-Toro M, Pascual-Leone A, Romera M, González A, Micó J, Ibarra O, et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):546–8.
dc.source.bibliographicCitationGarcia-Toro M, Mayol A, Arnillas H, Capllonch I, Ibarra O, Crespı M, et al. Modest adjunctive benefit with transcranial magnetic stimulation in q medication-resistant depression. J Affect Disord. 2001;64:271–5.
dc.source.bibliographicCitationHausmann A, Kemmler G, Walpoth M, Mechtcheriakov S, Kramer-Reinstadler K, Lechner T, et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single centre, randomised, double blind, sham controlled “add on” trial. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):320–2.
dc.source.bibliographicCitationJin Y, Phillips B. A pilot study of the use of EEG-based synchronized Transcranial Magnetic Stimulation (sTMS) for treatment of Major Depression. BMC Psychiatry. 2014;14(1):13.
dc.source.bibliographicCitationKauffmann CD, Cheema MA, Miller BE. Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study. Depress Anxiety. 2004;19(1):59–62.
dc.source.bibliographicCitationKoerselman F, Laman DM, van Duijn H, van Duijn MAJ, Willems MAM. A 3-month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. J Clin Psychiatry. 2004 Oct;65(10):1323–8.
dc.source.bibliographicCitationPallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience. 2010 May 5;167(2):323–8.
dc.source.bibliographicCitationPlewnia C, Pasqualetti P, Große S, Schlipf S, Wasserka B, Zwissler B, et al. Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial. J Affect Disord. 2014 Mar;156:219–23.
dc.source.bibliographicCitationPoulet E, Brunelin J, Boeuve C, Lerond J, D’Amato T, Dalery J, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry. 2004 Sep;19(6):382–3.
dc.source.bibliographicCitationPrasser J, Schecklmann M, Poeppl TB, Frank E, Kreuzer PM, Hajak G,et al. Bilateral prefrontal rTMS and theta burst TMS as an add-on treatment for depression: a randomized placebo controlled trial. World J Biol Psychiatry. 2015 Jan;16(1):57–65.
dc.source.bibliographicCitationRossini D, Magri L, Lucca A, Giordani S, Smeraldi E, Zanardi R. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. J Clin Psychiatry. 2005 Dec;66(12):1569–75.
dc.source.bibliographicCitationRossini D, Lucca A, Zanardi R, Magri L, Smeraldi E. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res. 2005 Nov 15;137(1-2):1–10.
dc.source.bibliographicCitationUllrich H, Kranaster L, Sigges E, Andrich J, Sartorius A. Ultra-high-frequency left prefrontal transcranial magnetic stimulation as augmentation in severely ill patients with depression: a naturalistic sham-controlled, double-blind, randomized trial. Neuropsychobiology [Internet]. 2012;66(3):141–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22948250
dc.source.bibliographicCitationUllrich H, Kranaster L, Sigges E, Andrich J, Sartorius A. Ultra-high-frequency left prefrontal transcranial magnetic stimulation as augmentation in severely ill patients with depression: a naturalistic sham-controlled, double-blind, randomized trial. Neuropsychobiology [Internet]. 2012;66(3):141–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22948250
dc.source.bibliographicCitationZheng B, Zheng Z, Zou K, Yan T-T, Mo L-L, Chen Z-S, et al. [Study the effects of neuroplasticity on major depression disorder in rTMS combined with antidepressant treatments]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Jul;44(4):596–601.
dc.source.bibliographicCitationKaramustafalioglu O, Ozcelik B, Uzun U, Tankaya O, Alpak G, Cengiz Y. Augmentative repetitive transcranial magnetic stimulation treatment in medication resistant major depression. Int J Neuropsychopharmacol. 2010;13(Suppl 1):152.
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/

 

Reconocimientos: